Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255217 | 0.89 | PIK3CA (0.58) | CDK2GSK3BCDK4PIK3CAPIK3CB | |
| SCHEMBL3255561 | 0.83 | CDK2 (0.61) | CDK2CDK4PIK3CAPIK3CBPIK3CG | |
| SCHEMBL3253879 | 0.79 | IKBKB (0.53) | — | |
| SCHEMBL3252211 | 0.79 | CDK2 (0.73) | CDK2CDK4PIK3CAPIK3CBPIK3CG | |
| SCHEMBL3409641 | 0.78 | PIK3CA (0.49) | CDK2CDK4PIK3CAPIK3CBPIK3CG | |
| SCHEMBL3250151 | 0.78 | PIK3CA (0.40) | CDK2GSK3BCDK4PIK3CAPIK3CB | |
| SCHEMBL3253355 | 0.77 | PIK3CG (0.47) | CDK2GSK3BPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3251254 | 0.77 | CDK9 (0.55) | CDK2GSK3BPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3258123 | 0.76 | RET (0.59) | CDK2GSK3BCDK4PIK3CAPIK3CB | |
| SCHEMBL3253201 | 0.76 | SYK (0.49) | GSK3BPIK3CAPIK3CBPIK3CGJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521749-B8 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-22 | — | — | EP | claimed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | claimed |
| EP-1521749-A1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | Novartis AG (CH) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005282-A1 | PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | claimed |
| EP-1521749-B1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | MKI67, CCNI, PAH | CDK2 22/4885GSK3B 862/4885CDK4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.